Key result
Argatroban was successfully used as an alternative anticoagulant during off-pump coronary artery bypass grafting in a patient who developed heparin-induced thrombocytopenia.
Why the study?
Can argatroban be safely and effectively used as an alternative anticoagulant for off-pump coronary artery bypass grafting in a patient with heparin-induced thrombocytopenia?
Case Report (n=1)
No
Can argatroban be safely and effectively used as an alternative anticoagulant for off-pump coronary artery bypass grafting in a patient with heparin-induced thrombocytopenia?
Argatroban can be safely and effectively used as an alternative anticoagulant during off-pump CABG in patients who develop heparin-induced thrombocytopenia preoperatively.
Case report suggests argatroban feasibility in HIT during off-pump CABG; leaves open need for prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
恒有 et al. (2008) conducted a case report in Heparin-Induced Thrombocytopenia (HIT) and angina pectoris (n=1). Argatroban was evaluated on Successful completion of OPCAB and recovery of platelet count. Argatroban was successfully used as an alternative anticoagulant during off-pump coronary artery bypass grafting in a patient who developed heparin-induced thrombocytopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: